Esperion Therapeutics Inc (ESPR) Business Payback Period

Esperion Therapeutics (ESPR) is a biopharmaceutical innovator developing oral cholesterol-lowering treatments through extensive R&D. The company's P/E fluctuations reflect the market's valuation of earnings, with -109.60 representing the latest level. The company is building a unique therapy ecosystem for statin-intolerant patients. Patent protection and approvals in the US and Europe strengthen the business's competitive advantages.

ESPR (Esperion Therapeutics Inc) P/E Multiple history from 07/04/2022 to 07/25/2026

Comprehensive metric breakdowns and analytics for Esperion Therapeutics Inc (ESPR)

- market price and analyst price targets:

Market Price esperion.com|ESPR - Price Target Chart

- market capitalization details:

Market Capitalization Esperion|ESPR - Total Company Value

- book capitalization data:

Share Book Value Esperion Therapeutics|ESPR - Book Capitalization|Market-to-Book Ratio esperion.com|ESPR - Aggregate Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

ESPR - Net Income|Future Net Profit Esperion Therapeutics|ESPR - P/E Multiple|Future Price to Earnings Multiple Esperion Therapeutics, Inc.|ESPR - PEG Multiple|Company Value to EBITDA Esperion|ESPR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Esperion Therapeutics|ESPR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth esperion.com|ESPR - Earnings per share growth in current year|Net earnings per share change forecast for next year Esperion Therapeutics

- company sales and revenue statistics:

ESPR - Revenue and Sales Volume|Company Expected Sales Volume esperion.com|ESPR - Market Cap to Revenue|Forward P/S Multiple Esperion

Comprehensive company analysis:ESPR (esperion.com)

Flagship merchandise of Esperion Therapeutics

Esperion Therapeutics (ESPR) aims to secure a dominant niche in cholesterol therapy by expanding insurance coverage for its innovative drugs. The ratio of market capitalization to net income, illustrated on the company's P/E chart, quantifies the value of this potential, allowing investors to determine the premium paid for future earnings and avoid purchasing a stagnating asset during periods of unjustified market optimism.

Analysis of competing companies

Market Cap to Earnings regeneron.com REGN|Price to Earnings Ratio iRhythm (IRTC)|Business Payback Period Lantheus Holdings|Price to Earnings Ratio Mineralys Therapeutics Inc MLYS|HTFL (HeartFlow) - Market Cap to Net Income|Kestra Medical Technologies - P/E Multiple|Market Cap to Earnings amarincorp.com|anteristech.com (AVR) - Price to Earnings Ratio|Tenaya Therapeutics, Inc. - Company Value to Net Income|CVRX (CVRx, Inc) - P/E Multiple|Milestone Pharmaceuticals Inc (MIST) - Business Payback Period|Price to Earnings Ratio Cardiol Therapeutics (CRDL)|BEAT - Market Cap to Earnings|Price to Earnings Ratio Tenax Therapeutics, Inc. TENX|ADGM: Price to Earnings Multiple|BCDA: Price to Earnings Ratio|Company Value to Net Income VTAK (Catheter Precision Corporation)|ABIO (arcabio.com) - Price to Earnings Ratio|ACST: Market Price to Net Income Ratio|AVTE (Aerovate Therapeutics, Inc.) - P/E Multiple|VERV: Company Value to Net Income|P/E Multiple WINT